Antifungal application of nonantifungal drugs

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1055-1062

  Stylianou, Marios ^a   Kulesskiy, Evgeny ^b   Lopes, José Pedro ^a   Granlund, Margareta ^a   Wennerberg, Krister ^b   Urban, Constantin F ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMONAFIDE; AMOROLFINE; ANTIFUNGAL AGENT; ARTEMISININ; AURANOFIN; BIFONAZOLE; BLEOMYCIN; DISULFIRAM; FLUCONAZOLE; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; MEGESTROL ACETATE; MELENGESTROL ACETATE; METITEPINE MALEATE; MICONAZOLE; MYCLOBUTANIL; NYSTATIN; OXICONAZOLE; RAPAMYCIN; SERTACONAZOLE; STANOZOLOL; TAMOXIFEN CITRATE; TERBINAFINE; TIOCONAZOLE; TOSEDOSTAT; TRIFLUPERIDOL;

ANEMIA; ANGIONEUROTIC EDEMA; ANTIFUNGAL ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; FUNGUS CULTURE; FUNGUS GROWTH; HUMAN; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RHEUMATIC DISEASE; YEAST CELL;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; CANDIDA; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG REPOSITIONING; DRUG RESISTANCE, FUNGAL; GLYCINE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYDROXAMIC ACIDS; MICROBIAL SENSITIVITY TESTS; SMALL MOLECULE LIBRARIES;

EID: 84893495182     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01087-13     Document Type: Article

References (59)

1. Patterson TF. 2005. Advances and challenges in management of invasive mycoses. Lancet 366:1013-1025. http://dx.doi.org/10.1016/S0140-6736(05)67381-3.
2. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. 2006. Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents 27:359-366. http://dx.doi.org/10.1016/j.ijantimicag.2006.01.002.
3. Zilberberg MD, Shorr AF, Kollef MH. 2008. Secular trends in candidemiarelated hospitalization in the United States, 2000-2005. Infect. Control Hosp. Epidemiol. 29:978-980. http://dx.doi.org/10.1086/591033.
4. Falagas ME, Apostolou KE, Pappas VD. 2006. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur. J. Clin. Microbiol. Infect. Dis. 25:419-425. http://dx.doi.org/10.1007/s10096- 006-0159-2.
5. Bergamasco MD, Garnica M, Colombo AL, Nucci M. 2013. Epidemiology of candidemia in patients with hematologic malignancies and solid tumours in Brazil. Mycoses 56:256-263. http://dx.doi.org/10.1111/myc.12013.
6. Pfaller MA. 2012. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125:S3-S13. http://dx.doi.org/10. 1016/j.amjmed.2011.11.001.
7. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. 2011. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob. Agents Chemother. 55:561-566. http://dx.doi.org/10.1128/AAC.01079-10.
8. Sudbery P, Gow N, Berman J. 2004. The distinct morphogenic states of Candida albicans. Trends Microbiol. 12:317-324. http://dx.doi.org/10.1016/j.tim. 2004.05.008.
9. Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90:939-949. http://dx.doi.org/10.1016/S0092-8674(00)80358-X.
10. Bastidas RJ, Heitman J. 2009. Trimorphic stepping stones pave the way to fungal virulence. Proc. Natl. Acad. Sci. U. S. A. 106:351-352. http://dx.doi.org/10.1073/pnas.0811994106.
11. Coleman DC, Moran GP, McManus BA, Sullivan DJ. 2010. Mechanisms of antifungal drug resistance in Candida dubliniensis. Future Microbiol. 5:935-949. http://dx.doi.org/10.2217/fmb.10.51.
12. Moran GP, Coleman DC, Sullivan DJ. 2012. Candida albicans versus Candida dubliniensis: why is C. albicans more pathogenic? Int. J. Microbiol. 2012:205921. http://dx.doi.org/10.1155/2012/205921.
13. Khan Z, Ahmad S, Joseph L, Chandy R. 2012. Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen. PLoS One 7:e32952. http://dx.doi.org/10.1371/journal.pone.0032952.
14. Lee I, Fishman NO, Zaoutis TE, Morales KH, Weiner MG, Synnestvedt M, Nachamkin I, Lautenbach E. 2009. Risk factors for fluconazoleresistant Candida glabrata bloodstream infections. Arch. Intern. Med. 169:379-383. http://dx.doi.org/10.1001/archinte.169.4.379.
15. Khan ZK, Jain P. 2000. Antifungal agents and immunomodulators in systemic mycoses. Indian J. Chest Dis. Allied Sci. 42:345-355.
16. Dixon DM, Walsh TJ. 1996. Chapter 76: antifungal agents. In Baron S (ed), Medical microbiology, 4th ed. University of Texas Medical Branch at Galveston, Galveston, TX.
17. Vermes A, Guchelaar HJ, Dankert J. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46:171-179. http://dx.doi.org/10.1093/ jac/46.2.171.
18. Beyda ND, Lewis RE, Garey KW. 2012. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann. Pharmacother. 46:1086-1096. http://dx.doi.org/10.1345/aph.1R020.
19. Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Lopez Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K. 1 September 2013. Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. http://dx.doi.org/10.1158/2159-8290.CD-13-0350.
20. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W, EUCASTAFST. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
21. Ericson E, Gebbia M, Heisler LE, Wildenhain J, Tyers M, Giaever G, Nislow C. 2008. Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. PLoS Genet. 4:e1000151. http://dx.doi.org/10.1371/journal.pgen. 1000151.
22. Allen SL, Lundberg AS. 2011. Amonafide: a potential role in treating acute myeloid leukemia. Expert Opin. Investig. Drugs 20:995-1003. http://dx.doi.org/10.1517/13543784.2011.585756.
23. Lowenberg B, Morgan G, Ossenkoppele GJ, Burnett AK, Zachée P, Dührsen U, Dierickx D, Müller-Tidow C, Sonneveld P, Krug U, Bone E, Flores N, Richardson AF, Hooftman L, Jenkins C, Zweegman S, Davies F. 2010. Phase I/II clinical study of tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 28:4333-4338. http://dx.doi.org/10.1200/JCO.2009.27.6295.
24. Ganellin CR, Triggle DJ, Macdonald F. 1997. Dictionary of Pharmacological Agents. Chapman & Hall, London, United Kingdom.
25. Butts A, DiDone L, Koselny K, Baxter BK, Chabrier-Rosello Y, Wellington M, Krysan DJ. 2013. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot. Cell 12:278-287. http://dx.doi.org/10.1128/EC.00314-12.
26. Sehgal SN, Baker H, Vézina C. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28:727-732.
27. Ozdemir I, Temelli N, Günal S, Demir S. 2010. Gold(I) complexes of N-heterocyclic carbene ligands containing benzimidazole: synthesis and antimicrobial activity. Molecules 15:2203-2210. http://dx.doi.org/10.3390/ molecules15042203.
28. Brown GD, Denning DW, Levitz SM. 2012. Tackling human fungal infections. Science 336:647. http://dx.doi.org/10.1126/science.1222236.
29. Meshulam T, Levitz SM, Christin L, Diamond RD. 1995. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanil ide (XTT). J. Infect. Dis. 172:1153-1156. http://dx.doi.org/10.1093/infdis/172.4. 1153.
30. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, Brinkmann V, Jungblut PR, Zychlinsky A. 2009. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 5:e1000639. http://dx.doi.org/10.1371/journal. ppat.1000639.
31. Nunnari JM. 2010. qHTS assay for small molecule inhibitors of mitochondrial division or activators of mitochondrial fusion. PubChem BioAssay AID 485298. National Center for Biotechnology Information, Bethesda,MD.http:// pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid-485298.
32. Martin MV, Dinsdale RC. 1982. Nystatin-resistance of Candida albicans isolates from two cases of oral candidiasis. Br. J. Oral Surg. 20:294-298.
33. Mas J, Piña E. 1980. Disappearance of nystatin resistance in Candida mediated by ergosterol. J. Gen. Microbiol. 117:249-252.
34. Broughton MC, Bard M, Lees ND. 1991. Polyene resistance in ergosterol producing strains of Candida albicans. Mycoses 34:75-83.
35. Miwa T, Takagi Y, Shinozaki M, Yun CW, Schell WA, Perfect JR, Kumagai H, Tamaki H. 2004. Gpr1, a putative G-protein-coupled receptor, regulates morphogenesis and hypha formation in the pathogenic fungus Candida albicans. Eukaryot. Cell 3:919-931. http://dx.doi.org/10.1128/EC.3.4.919-931.2004.
36. Sciascia QL, Sullivan PA, Farley PC. 2004. Deletion of the Candida albicans G-protein-coupled receptor, encoded by orf19.1944 and its allele orf19.9499, produces mutants defective in filamentous growth. Can. J. Microbiol. 50:1081-1085. http://dx.doi.org/10.1139/w04-095.
37. Krige D, Needham LA, Bawden LJ, Flores N, Farmer H, Miles LE, Stone E, Callaghan J, Chandler S, Clark VL, Kirwin-Jones P, Legris V, Owen J, Patel T, Wood S, Box G, Laber D, Odedra R, Wright A, Wood LM, Eccles SA, Bone EA, Ayscough A, Drummond AH. 2008. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 68:6669-6679. http://dx.doi.org/10.1158/0008-5472.CAN-07-6627.
38. Cruz MC, Goldstein AL, Blankenship J, Del Poeta M, Perfect JR, McCusker JH, Bennani YL, Cardenas ME, Heitman J. 2001. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob. Agents Chemother. 45:3162-3170. http://dx.doi.org/10.1128/AAC.45.11.3162-3170.2001.
39. Baxter J, Diffley JF. 2008. Topoisomerase II inactivation prevents the completion of DNA replication in budding yeast. Mol. Cell 30:790-802. http://dx.doi.org/10.1016/j.molcel.2008.04.019.
40. Jayaguru P, Raghunathan M. 2007. Group I intron renders differential susceptibility of Candida albicans to bleomycin. Mol. Biol. Rep. 34:11-17. http://dx.doi.org/10.1007/s11033-006-9002-1.
41. Khan S, Singhal S, Mathur T, Upadhyay DJ, Rattan A. 2007. Antifungal potential of disulfiram. Nihon Ishinkin Gakkai Zasshi 48:109-113. http://dx.doi.org/10.3314/jjmm.48.109.
42. Galal AM, Ross SA, Jacob M, ElSohly MA. 2005. Antifungal activity of artemisinin derivatives. J. Nat. Prod. 68:1274-1276. http://dx.doi.org/10.1021/ np050074u.
43. Dolan K, Montgomery S, Buchheit B, Didone L, Wellington M, Krysan DJ. 2009. Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob. Agents Chemother. 53: 3337-3346. http://dx.doi.org/10.1128/AAC.01564-08.
44. Kudo S, Ishizaki T. 1999. Pharmacokinetics of haloperidol: an update. Clin. Pharmacokinet. 37:435-456. http://dx.doi.org/10.2165/00003088-199937060- 00001.
45. Zofková I, Kancheva RL, Hampl R. 1995. A decreasing CD4/CD8 ratio after one month of treatment with stanazolol in postmenopausal women. Steroids 60:430-433. http://dx.doi.org/10.1016/0039-128X(94) 00036-C.
46. Tsukada A, Suemizu H, Murayama N, Takano R, Shimizu M, Nakamura M, Yamazaki H. 2013. Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. Regul. Toxicol. Pharmacol. 65:316-324. http://dx.doi.org/10.1016/j.yrtph.2013.01.008.
47. Femia RA, Goyette RE. 2005. The science of megestrol acetate delivery: potential to improve outcomes in cachexia. BioDrugs 19:179-187. http://dx.doi.org/10.2165/00063030-200519030-00004.
48. Blodgett RC, Jr. 1983. Auranofin: experience to date. Am. J. Med. 75:86-89. http://dx.doi.org/10.1016/0002-9343(83)90480-1.
49. Zimmerman JJ, Kahan BD. 1997. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J. Clin. Pharmacol. 37:405-415. http://dx.doi.org/10.1002/j.1552-4604.1997.tb04318.x.
50. Granger B, Albu S. 2005. The haloperidol story. Ann. Clin. Psychiatry 17:137-140. http://dx.doi.org/10.1080/10401230591002048.
51. Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA. 1992. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol. Pharmacol. 41:494-508.
52. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526. http://dx.doi.org/10.1038/sj.npp.1300027.
53. Gallant DM, Bishop MP, Timmons E, Steele CA. 1963. A controlled evaluation of trifluperidol: a new potent sychopharmacologic agent. Curr. Ther. Res. Clin. Exp. 5:463-471.
54. Resegotti L, Dolci C, Bertero L, Genovese A, Podestà F, Testa D. 1981. Treatment of aplastic anaemia with methenolone, stanozolol and nandrolone. A report of 130 cases. Panminerva Med. 23:243-248.
55. Sheffer AL, Fearon DT, Austen KF. 1987. Hereditary angioedema: a decade of management with stanozolol. J. Allergy Clin. Immunol. 80:855-860. http://dx.doi.org/10.1016/S0091-6749(87)80277-4.
56. Cooper JM, Elce JS, Kellie AE. 1967. The metabolism of melengestrol acetate. Biochem. J. 104:57P-58P.
57. Perry GA, Welshons WV, Bott RC, Smith MF. 2005. Basis of melengestrol acetate action as a progestin. Domest. Anim. Endocrinol. 28: 147-161. http://dx.doi.org/10.1016/j.domaniend.2004.07.002.
58. Johnson PA, Bonomi PD, Anderson KM, Wolter JM, Economou SG. 1986. Megestrol acetate: first-line therapy for advanced breast cancer. Semin. Oncol. 13:15-19.
59. Ross MB, Buzdar AU, Blumenschein GR. 1982. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 49:413-417. http://dx.doi.org/10.1002/1097-0142(19820201)49:3'413:: AID-CNCR2820490303+3.0. CO;2-S.